Bio Pharma Dive

MARCH 7, 2023

Rapport Therapeutics aims to find new so-called receptor-associated proteins that could serve as targets for neurological disease medicines. Its most advanced drug is already in early-stage human testing.

Drugs 362

Drugs Protein Medicine 362

Medical Xpress

JANUARY 18, 2025

Researchers at Baylor College of Medicine and collaborating institutions have improved our understanding of how rotavirus, the most common cause of acute gastroenteritis in children, makes people sick.

Protein 83

Protein Medicine Research 83

Bio Pharma Dive

MAY 18, 2021

The pharma acquired rights to an experimental antibody medicine that blocks a protein, called TIGIT, that's become a focus for several cancer drugmakers.

Protein 337

Protein Antibody Medicine Drugs 337

Bio Pharma Dive

DECEMBER 9, 2021

The amount of blood clotting protein found in patients who received the medicine was nearly the same at six months and 18 months post-treatment, according to results disclosed Thursday.

Gene Therapy 332

Gene Therapy Gene Protein Medicine 332

Bio Pharma Dive

OCTOBER 20, 2022

The deal gives AbbVie an experimental medicine for idiopathic pulmonary fibrosis, as well as a platform for designing antibody drugs that can target proteins known as GPCRs.

Protein 326

Protein Antibody Medicine Drugs 326

Pharmaceutical Technology

JUNE 20, 2023

Developed using pharmaceutical company GSK’s pandemic adjuvant, the vaccine targets the receptor-binding domain of the SARS-CoV-2 spike protein. The vaccine is based on recombinant protein vaccine technology and is suitable for storage between 2°C and 8°C. “We

Vaccination 363

Vaccination Vaccine Protein Clinical Trials 363

Bio Pharma Dive

OCTOBER 24, 2023

The startup is taking aim at an inflammation-linked protein known as TSLP, which is the target of an approved asthma medicine.

Protein 306

Protein Medicine Drugs 306

Bio Pharma Dive

OCTOBER 26, 2022

It joins a group of medicines on market that target a protein called BCMA. The treatment, which will be sold as Tecvayli, is the first bispecific antibody cleared for the disease.

Protein 290

Protein Antibody Medicine Drugs 290

Bio Pharma Dive

MARCH 11, 2024

Sosei Heptares could receive more than 700 million euros in a deal to develop medicines aimed at the protein GPR52, an emerging drug target in multiple neurological diseases.

Drugs 278

Drugs Protein Medicine Development 278

Pharmaceutical Technology

JULY 7, 2022

But scientists have struggled to find effective treatments for many of these diseases since the dawn of modern medicine. Often referred to as a type of gene-modified cell therapy, CAR-T cell therapies involve genetically modifying a patient’s own T cells to produce a protein that enables them to identify and kill cancer cells.

Gene Therapy 245

Gene Therapy Gene Medicine Genetics 245

Pharmaceutical Technology

MARCH 11, 2024

Discover how Revolution Medicines Inc. is revolutionizing cancer treatment with their patented macrocyclic compounds targeting Ras proteins. Learn more about their potential impact on various types of cancer and Ras mutations.

Protein 100

Protein Medicine 100

Bio Pharma Dive

APRIL 5, 2023

Public records and job postings show Resonance Medicine, which has ties to several high-profile venture capital firms, aims to reprogram protein-cutting enzymes to treat disease.

Protein 258

Protein Medicine 258

Bio Pharma Dive

AUGUST 28, 2023

GPCRs, a ubiquitous family of proteins that are prime drug targets, have drawn the interest of companies like Structure Therapeutics, Septerna and now Superluminal Medicines.

Drugs 246

Drugs Protein Medicine 246

Pharma Times

DECEMBER 20, 2023

Researchers from Johns Hopkins University School of Medicine have revealed new findings about a key pathological protein associated with Parkinson’s disease (PD), which could lead to new treatments. However, its relation to dopaminergic neuron death is unclear.

Protein 121

Protein Medicine Engineer Genetics 121

Worldwide Clinical Trials

JUNE 13, 2024

Despite the higher yield, both sample types showed minimal protein contamination, indicating high purity levels. This high compliance rate is crucial for the successful implementation of personalized medicine, as it ensures a larger and more diverse patient population can benefit from PGx insights.

Medicine 182

Medicine DNA Compliance Clinical Trials 182

Pharmaceutical Technology

MAY 30, 2023

SK Bioscience has received marketing authorisation from the UK’s medicines and healthcare products regulatory agency (MHRA) for its Covid-19 vaccine, SKYCovion. SKYCovion, a protein-based vaccine created in collaboration with GSK’s pandemic adjuvant, is suitable for storage between 2° and 8° Celsius.

Vaccination 298

Vaccination Vaccine Protein Medicine 298

AuroBlog - Aurous Healthcare Clinical Trials blog

JULY 15, 2024

Twisted and tangled proteins are found in the brains of many of those who die with Alzheimer’s disease. A promising new medicine has now […] Some scientists suspect these neural knots can harm and even kill brain cells, but so far in clinical trials, drugs that have tried to target the tangles have shown limited success.

Clinical Trials 246

Clinical Trials Clinical Trials Protein Scientist 246

AuroBlog - Aurous Healthcare Clinical Trials blog

APRIL 2, 2024

Alzheimer’s disease is commonly associated with clumps and tangles of proteins building up in brain cells. A study led by researchers from the Stanford University School of Medicine returned to observations of large fat drops […]

Protein 233

Protein Medicine Research Clinical Trials 233

Pharmaceutical Technology

MAY 17, 2023

It will use the precision medicine approach, as well as the deep expertise of Chinook Therapeutics in nephrology and knowledge of Ionis Pharmaceuticals in RNA-targeted therapeutics. Antisense therapies are designed for destroying mRNA, reducing the amount of disease-causing protein.

Development 246

Development Protein RNA Genetics 246

Pharmaceutical Technology

JANUARY 3, 2023

Blacksmith Medicines has signed a definitive merger agreement with Forge Therapeutics to create a combined entity that will discover and develop medicines targeting a large class of proteins called metalloenzymes. The merged entity will focus on developing medicines with an initial focus on oncology and infection.

Medicine 130

Medicine DNA Genome Genomics 130

Scienmag

JULY 15, 2021

New artificial intelligence software can compute protein structures in 10 minutes Credit: Ian Haydon, UW Medicine Institute for Protein Design Scientists have waited months for access to highly accurate protein structure prediction since DeepMind presented remarkable progress in this area at the 2020 Critical Assessment of Structure Prediction, or (..)

Protein 98

Protein Scientist Medicine Engineer 98

Pharmaceutical Technology

AUGUST 5, 2022

As per the prevailing prion theory, a misfolded version of a normal cell-surface protein acts as the chief infectious agent. It is ultra-rare,” says Jesús Rodriguez Requena, PhD, associate professor in the Department of Medicine at the University of Santiago de Compostela. And then comes the question of the right target.

Drugs 299

Drugs Protein Vaccination Vaccine 299

Medical Xpress

FEBRUARY 22, 2023

Medicines that are based on mRNAs and proteins—particularly vaccines and antibodies—are time-intensive and costly to make. The challenge is in producing the necessary mRNAs and proteins in large enough amounts at low cost.

Protein 71

Protein Medicine Production Antibody 71

Medical Xpress

NOVEMBER 8, 2022

Researchers at the University of Maryland School of Medicine's (UMSOM) Center for Precision Disease Modeling identified how a specific protein in SARS-CoV-2, the virus responsible for COVID-19, damages heart tissue. They then used a drug to reverse the toxic effects of that protein on the heart.

Protein 98

Protein Medicine Drugs Research 98

Bio Pharma Dive

FEBRUARY 15, 2024

Armed with $94 million in funding, the biotech is marrying antibody-drug conjugates with protein degraders to create a new kind of cancer medicine.

Protein 189

Protein Antibody Medicine Drugs 189

Pharmaceutical Technology

NOVEMBER 11, 2022

The European Commission (EC) has granted approval for Sanofi and GSK ’s monovalent, recombinant-protein-based, adjuvanted Covid-19 vaccine, VidPrevtyn Beta, as a booster in adults aged 18 years and above. It is indicated as a booster in people of this age group who were earlier inoculated with a Covid-19 vaccine.

Vaccination 246

Vaccination Vaccine Immune Response Protein 246

Medical Xpress

FEBRUARY 16, 2023

An adenovirus serotype 26 respiratory syncytial virus (RSV) vector encoding a prefusion F (preF) protein (Ad26.RSV.preF) RSV.preF) in combination with RSV preF protein is immunogenic and prevents RSV-mediated lower respiratory tract disease in older adults, according to a study published in the Feb.

Protein 89

Protein Vaccination Vaccine Medicine 89

Pharmaceutical Technology

SEPTEMBER 14, 2022

API peptides and proteins-based drugs have gained much attention in the past decade. Discover the top API protein and peptide companies in contract marketing. Technologies in the delivery of peptides and proteins. They are promising therapeutics for the treatment of a variety of metabolic and oncological disorders.

Protein 100

Protein Marketing Manufacturing Reagent 100

Bio Pharma Dive

MAY 7, 2024

The company is using what it claims is the largest database of viral protein structures to unearth medicines for a range of diseases, said CEO and Flagship origination partner Lovisa Afzelius.

Protein 161

Protein Medicine Drugs 161

Pharmaceutical Technology

APRIL 27, 2023

Orbital will use the new funding to increase the application of RNA-based medicines for use in the fields of new vaccines, immunomodulation and protein replacement. New investors included the Redmile Group, the Abu Dhabi Growth Fund (ADG), Exor, Invus, Moore Strategic Ventures, the iGlobe Platinum Fund Group and Casdin Capital.

RNA 130

RNA Medicine Gene Therapy Gene 130

XTalks

DECEMBER 12, 2023

Plasma medicine is a critical and specialized field within healthcare, centering on the use of human plasma for the development and administration of life-saving treatments. Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

Pharmaceutical Technology

APRIL 13, 2023

Clinical-stage biopharmaceutical firm Alentis Therapeutics has raised $105m in a Series C financing round for advancing transformational medicines targeting the CLAUDIN-1 protein.

Medicine 130

Medicine Development Antibody Engineer 130

Pharmaceutical Technology

OCTOBER 18, 2022

Last week, Nature magazine published a paper detailing an in-situ study of Parkinson’s disease (PD), showing protein structural changes in cerebrospinal fluid (CSF) between healthy individuals and Parkinson’s patients. Genetic biomarkers are being investigated to aid in the development of precision medicine for PD.

Protein 264

Protein Genetics Gene Clinical Research 264

pharmaphorum

SEPTEMBER 14, 2020

Here he gives us a deeper look at how genomic medicine is evolving and the barriers that are preventing it from reaching its full potential. At that time, we thought this would be the holy grail for medicine. Now, however, the field is changing with respect to genomic medicine.

Genome 119

Genome Genomics Medicine Gene 119

Scienmag

DECEMBER 23, 2021

Blocking function of a blood-clotting protein prevented bone loss from periodontal (gum) disease in mice, according to research led by scientists at the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health.

Protein 92

Protein Scientist Research Medicine 92

XTalks

NOVEMBER 26, 2024

This progressive disease occurs when misfolded transthyretin (TTR) proteins form amyloid deposits in the heart, leading to cardiac dysfunction. A Marketing Authorization Application has been submitted to the European Medicines Agency (EMA), with a decision anticipated in 2025.

Genetic Disease 105

Genetic Disease Genetics Protein Clinical Development 105

Scienmag

JULY 25, 2021

This Oncotarget study confirms the upregulation of TERT in primary glioblastomas while all GABP proteins rise with the malignancy of the gliomas Credit: Correspondence to – Marco Timmer – marco.timmer@uk-koeln.de

Protein 97

Protein Medicine 97